Drugs that are generally accepted to prolong the QT interval and have an increased risk of torsades de pointes
Amiodarone, arsenic trioxide, astemizole, bepridil, chloroquine, chlorpromazine, cisapride, clarithromycin, disopyramide, dofetilide, domperidone, droperidol, erythromycin, halofantrine, haloperidol, ibutilide, levomethadyl, mesoridazine, methadone, pentamidine, pimozide, probucol, procainamide, quinidine, sotalol, sparfloxacin, terfenadine, thioridazine
Drugs that may prolong the QT interval and have an increased risk of torsades de pointes
Alfuzosin, amantadine, atazanavir, chloral hydrate, clozapine, dolasetron, dronedarone, escitalopram, felbamate, flecainaide, foscarnet, gatifloxacin, gemifloxacin, granisetron, indapamide, isradipine, lapatinib, levofloxacin, lithium, moxifloxacin, nicardipine, nilotinib, octreotide, ofloxacin, oxytocin, paliperidone, quetiapine, ranolazine, risperidone, sertindole, sunitinib, tacrolimus, tamoxifen, telithromycin, tizanidine, vardenafil, venlafaxine, voriconazole, ziprasidone
Drugs that prolong the PR interval
Acetylcholinesterase inhibitors (donepezil, rivastigmine, galantamine), adenosine, alendronate, anti-arrhythmics (flecainide, propafenone, procainamide), beta blockers, calcium channel blockers, digoxin, dolasetron, lithium, HIV protease inhibitors, TCAs, pregabalin, lacosamide, methyldopa, vitamin D and derivatives
Drugs that shorten the PR interval
Atropine, ibutilide